Prices are updated after-hours

genomic

Qiagen N.V.

QGEN | $41.52 -0.88% 0.0% 820K

(0.0% 1d) (-2.2% 1m) (-5.1% 1y) (0.0% 2d) (1.6% 3d) (4.7% 7d) (-15.96% volume)
Earnings Calendar:
Market Cap: $ 9,474,978,388
http://www.qiagen.com
Sec Filling | Patents | 5096 employees

(NL) QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

genomic molecular diagnostics diagnostics

add to watch list Paper trade email alert is off

EVOLUTIONARY GENOMICS, INC.

FNAM 4 | $0.45 0% 300

(0.0% 1d) (0.0% 1m) (-32.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-70.0% volume)
Earnings Calendar:
Market Cap: $ 2,959,529

Sec Filling | Patents | 3 employees

evolutionary genomics is a research company located in 1376 miners dr, lafayette, colorado, united states.

add to watch list Paper trade email alert is off

LogicBio Therapeutics, Inc.

LOGC | $2.07 -0.48%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-0.5% 7d) (NaN% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 68,232,857
http://www.logicbio.com
Sec Filling | Patents | 41 employees

(US) LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.

genomic genome editing

add to watch list Paper trade email alert is off

Bionano Genomics, Inc.

BNGO | $0.7655 -3.64% -3.78% 790K

Health Technology

(0.0% 1d) (-23.3% 1m) (7.4% 1y) (0.0% 2d) (3.9% 3d) (5.3% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 41,868,257
http://www.bionanogenomics.com
Sec Filling | Patents | 97 employees

(US) Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.

cytogenetics genomic diagnostics

add to watch list Paper trade email alert is off

Editas Medicine, Inc.

EDIT | News | $5.355 -1.92% -1.96% 1.6M

Health Technology

(0.0% 1d) (-25.8% 1m) (-29.1% 1y) (0.0% 2d) (-2.5% 3d) (-1.6% 7d) (15.76% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 440,366,872
http://www.editasmedicine.com
Sec Filling | Patents | 208 employees

(US) Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

genomic genome editing crispr

add to watch list Paper trade email alert is off

Intellia Therapeutics, Inc.

NTLA | $21.16 -1.72% -1.75% 860K

Health Technology

(0.0% 1d) (-19.8% 1m) (-40.6% 1y) (0.0% 2d) (-1.4% 3d) (1.0% 7d) (1.18% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 2,040,640,945
http://www.intelliatx.com
Sec Filling | Patents | 270 employees

(US) Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

crispr genomic genome editing glass

add to watch list Paper trade email alert is off

Sangamo Therapeutics, Inc.

SGMO | News | $0.4911 -5.72% -6.07% 1.2M

Health Technology

(0.0% 1d) (-19.0% 1m) (-67.7% 1y) (0.0% 2d) (2.0% 3d) (2.0% 7d) (-49.2% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 101,901,094
http://www.sangamo.com
Sec Filling | Patents | 354 employees

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

gene therapies genomic autoimmunity genome editing urea immunology t-cell nervous system metabolic ceiling

add to watch list Paper trade email alert is off

10x Genomics, Inc.

TXG | $27.525 -0.2% -0.2% 1.6M

Health Technology

(0.0% 1d) (-24.0% 1m) (-45.9% 1y) (0.0% 2d) (-0.8% 3d) (-1.3% 7d) (-9.6% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 2,907,804,335
http://www.10xgenomics.com
Sec Filling | Patents | 584 employees

(US) 10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

genomic t-cell ceiling profitable

add to watch list Paper trade email alert is off

Lantern Pharma Inc.

LTRN | News | $5.44 -5.72% -6.07% 96K

Health Technology

(0.0% 1d) (-41.8% 1m) (26.5% 1y) (0.0% 2d) (0.9% 3d) (8.1% 7d) (-23.15% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 58,432,803
http://www.lanternpharma.com
Sec Filling | Patents | 13 employees

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

genomic artificial intelligence lp-10 machine learning

add to watch list Paper trade email alert is off

Singular Genomics Systems Inc

OMIC | $0.4144 3.38% 34K

Professional, Scientific, and T...

(0.0% 1d) (-18.8% 1m) (-59.0% 1y) (0.0% 2d) (2.5% 3d) (2.5% 7d) (-56.16% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 30,701,029
https://singulargenomics.com
Sec Filling | Patents | 138 employees

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

t-cell

add to watch list Paper trade email alert is off

Silence Therapeutics Plc

SLN | $22.33 -0.8% -0.81% 110K

Health Technology

(0.0% 1d) (3.0% 1m) (388.3% 1y) (0.0% 2d) (0.0% 3d) (-0.6% 7d) (-31.24% volume)
Earnings Calendar:
Market Cap: $ 668,297,599
http://silence-therapeutics.com
Sec Filling | Patents | 74 employees

(United Kingdom) Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

genomic t-cell ceiling

add to watch list Paper trade email alert is off

CRISPR Therapeutics AG

CRSP | News 4 | $55.66 -1.33% -1.35% 910K

Health Technology

(0.0% 1d) (-20.6% 1m) (14.1% 1y) (0.0% 2d) (1.3% 3d) (2.5% 7d) (-22.69% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 4,724,592,845
http://www.crisprtx.com
Sec Filling | Patents | 304 employees

(CH) CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

genomic genome editing crispr

add to watch list Paper trade email alert is off

Precision BioSciences, Inc.

DTIL | $9.81 -4.11% -4.28% 34K

Health Technology

(0.0% 1d) (-13.3% 1m) (1060.7% 1y) (0.0% 2d) (5.7% 3d) (-4.6% 7d) (8.1% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 67,848,305
http://www.precisionbiosciences.com
Sec Filling | Patents | 199 employees

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

genomic nutrition genome editing food

add to watch list Paper trade email alert is off

Qiagen N.V.

QGEN | $41.52 -0.88% 0.0% 820K

Health Technology

Agilent Technologies, Inc.

A | $137.49 -1.23% -0.36% 1.6M

Health Technology

(0.0% 1d) (-4.4% 1m) (6.8% 1y) (0.0% 2d) (4.0% 3d) (4.9% 7d) (-21.53% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 40,292,170,997
http://www.agilent.com
Sec Filling | Patents | n/a employees

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment comprises activity providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

genomic urea diagnostics msa

Drugs

Hand Sanitizer (Isopropyl Alcohol)

add to watch list Paper trade email alert is off

Biodesix, Inc.

BDSX | $1.26 -1.56% -1.59% 7.1K

Health Services

(0.0% 1d) (-11.1% 1m) (-20.0% 1y) (0.0% 2d) (-0.8% 3d) (2.4% 7d) (Infinity% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 122,146,997
http://www.biodesix.com
Sec Filling | Patents | n/a employees

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.

cancer lung cancer genomic t-cell lungs diagnostics ceiling

add to watch list Paper trade email alert is off

Blueprint Medicines Corporation

BPMC | $92.31 0.02% 0.02% 560K

Health Technology

(0.0% 1d) (4.6% 1m) (88.9% 1y) (0.0% 2d) (1.9% 3d) (5.0% 7d) (-25.38% volume)
Earnings Calendar: 2023-10-26
Market Cap: $ 5,649,372,000
http://www.blueprintmedicines.com
Sec Filling | Patents | 383 employees

(US) Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

cancer genomic immunotherapy

Drugs

Ayvakit (avapritinib)
GAVRETO (pralsetinib)

add to watch list Paper trade email alert is off

DermTech, Inc.

DMTK 4 | $0.616 3.81% 72K

Health Technology

(0.0% 1d) (-6.1% 1m) (-83.1% 1y) (0.0% 2d) (3.3% 3d) (-3.1% 7d) (-57.49% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 21,328,041
http://www.dermtech.com
Sec Filling | Patents | 116 employees

DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company was founded in 1995 and is headquartered in La Jolla, CA.

skin cancer genomic diagnostics treatment

add to watch list Paper trade email alert is off

Personalis, Inc.

PSNL | $1.3 -5.8% -6.15% 160K

Health Technology

(0.0% 1d) (-4.2% 1m) (-37.3% 1y) (0.0% 2d) (9.5% 3d) (7.0% 7d) (-7.89% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 65,655,056
http://www.personalis.com
Sec Filling | Patents | 182 employees

(US) Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

vaccine cancer genomic immunotherapy

add to watch list Paper trade email alert is off

Tucows Inc.

TCX | $17.98 2.16% 2.11% 40K

Technology Services

(0.0% 1d) (-0.2% 1m) (-20.4% 1y) (0.0% 2d) (-0.1% 3d) (0.5% 7d) (82.15% volume)
Earnings Calendar:
Market Cap: $ 194,718,204
http://www.tucowsinc.com
Sec Filling | Patents | 633 employees

(CA) Tucows, Inc. is an Internet services company. The firm engages in the provision of domain names, email and other internet services. It operates through the following segments: Network Access Services and Domain Services. The Network Access Services segment includes mobile, fixed high speed Internet access services and other revenue sources, including billing solutions to small Internet service providers. The Domain Services segment includes wholesale and retail domain name registration services; value added services and portfolio services derived through OpenSRS, eNom, Ascio and Hover brands. The company was founded in November 1992 and is headquartered in Toronto, Canada.

genomic brands

add to watch list Paper trade email alert is off